The no-reflow phenomenon in the coronary circulation

Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):181-92. doi: 10.2174/187152509789105426.

Abstract

The no-reflow phenomenon is a poorly understood complication of percutaneous coronary intervention in which diminished blood flow to distal microvascular beds persists despite the successful treatment of the occlusive lesion from the epicardial coronary artery or arteries. In this contemporary review we endeavour to discuss the pathophysiology of coronary no-reflow, understand the predictors and describe current pharmacological and mechanical strategies to prevent and treat coronary no-reflow.

Publication types

  • Review

MeSH terms

  • Adenosine / therapeutic use
  • Animals
  • Coronary Circulation*
  • Diltiazem / therapeutic use
  • Humans
  • Nicardipine / therapeutic use
  • Nicorandil / therapeutic use
  • Nitroprusside / therapeutic use
  • No-Reflow Phenomenon / drug therapy*
  • No-Reflow Phenomenon / physiopathology*
  • No-Reflow Phenomenon / therapy
  • Prostheses and Implants
  • Vasodilator Agents / therapeutic use
  • Verapamil / therapeutic use

Substances

  • Vasodilator Agents
  • Nitroprusside
  • Nicorandil
  • Verapamil
  • Nicardipine
  • Diltiazem
  • Adenosine